Carmat reaches half of EFICAS recruitment target

(CercleFinance.com) - Carmat has announced that it has reached the halfway mark in its recruitment targets for the EFICAS study.


The 26th Aeson® implantation recently carried out as part of the EFICAS study has enabled Carmat to reach the halfway mark in the 52 recruitment targets for this study, which is being carried out exclusively in France.

Of the 10 hospitals participating in the study, 9 have already carried out at least one implantation, and 8 have already carried out at least two.

As a reminder, the EFICAS study is the largest study ever initiated by Carmat. It is a key study both for obtaining reimbursement for Aeson® in France, and for obtaining "PMA" (marketing authorization for Aeson® in the United States), which the Company anticipates for 2027 (subject in particular to the successful completion of the EFS study in the United States, whose second cohort is expected to start in the first quarter of 2025).

Stéphane Piat, Chief Executive Officer of Carmat, commented: "EFICAS is an essential study for scientifically objectifying the clinical results of Aeson® on a large sample of patients, and thus facilitating their dissemination within the medical community. If the final results of the study confirm the interim results, their publication at the end of 2025 should contribute to a strong acceleration in the adoption of Aeson® by European physicians'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.